Booz Allen Hamilton has won a contract with a ceiling of $147.4 million over five years to provide the National Institute of Allergy and Infectious Diseases with a complete range of technical support and service
NIAID, which is a part of the National Institutes of Health, has a key role in safeguarding U.S. public health domestically and globally, said Roman Salasznyk, vice president and Booz Allen life science lead.
“Their scientists conduct groundbreaking research to create vaccines and identify new lifesaving treatments, and are also called upon to rapidly respond in times of crisis like the Coronavirus epidemic,” he said.
“With a unique blend of knowledge in life science and deep expertise in federal IT modernization, Booz Allen’s tremendous pool of talent is well positioned to deliver modern, technical solutions to help the NIAID fulfill its mission,” he added.
NIAID has a unique dual mandate. It conducts and supports research to into infectious, immunologic and allergic diseases, and also rapidly responds to the emergence or reemergence of infectious diseases like influenza, malaria and more recently, corona virus.
Booz Allen will serve as a strategic partner in furthering the institute’s mission to expedite scientific discoveries, foster innovative research and strategies to improve public health, and ensure the nation’s disease-prevention capabilities. The company will aid NIAID’s Office of Computer Infrastructure and Computational Biology in developing and maintaining enterprise applications.